Table 1 U266 cells treated with... | American Society of Hematology

Table 1

U266 cells treated with resveratrol, bortezomib, and thalidomide alone or in combination

Resveratrol	Resveratrol	Bortezomib, % apoptosis			Thalidomide, % apoptosis
Resveratrol	Resveratrol	10 nM	20 nM	30 nM	5 μg/mL	10 μg/mL	20 μg/mL
0 μM	1 ± 0.57	5 ± 0.5	20 ± 1.63	45 ± 2.45	5 ± 0.82	15 ± 3.32	35 ± 2.45
15 μM	6 ± 0.82	12 ± 0.96	25 ± 1.15	45 ± 8.54	10 ± 1.63	20 ± 2.99	35 ± 6.45
25 μM	12 ± 2.06	25 ± 3.56	65 ± 4.08	92 ± 5.06	30 ± 1.15	55 ± 4.08	85 ± 4.08
30 μM	40 ± 2.98	60 ± 6.45	98 ± 1.15	100 ± 0.5	45 ± 4.08	90 ± 3.09	100 ± 0.5

Resveratrol	Resveratrol	Bortezomib, % apoptosis			Thalidomide, % apoptosis
Resveratrol	Resveratrol	10 nM	20 nM	30 nM	5 μg/mL	10 μg/mL	20 μg/mL
0 μM	1 ± 0.57	5 ± 0.5	20 ± 1.63	45 ± 2.45	5 ± 0.82	15 ± 3.32	35 ± 2.45
15 μM	6 ± 0.82	12 ± 0.96	25 ± 1.15	45 ± 8.54	10 ± 1.63	20 ± 2.99	35 ± 6.45
25 μM	12 ± 2.06	25 ± 3.56	65 ± 4.08	92 ± 5.06	30 ± 1.15	55 ± 4.08	85 ± 4.08
30 μM	40 ± 2.98	60 ± 6.45	98 ± 1.15	100 ± 0.5	45 ± 4.08	90 ± 3.09	100 ± 0.5

U266 cells (1 × 10⁶/mL) were treated with indicated concentrations of resveratrol, bortezomib, and thalidomide alone or in combination for 24 hours at 37°C. Cells were stained with a live/dead assay reagent for 30 minutes and then analyzed under a fluorescence microscope as described in “Materials and methods.” The results shown are the percentage of apoptosis and are representative of 3 independent experiments. Standard deviations between the triplicates are indicated.

View Large

This Feature Is Available To Subscribers Only